Skip to content
value.today

Constellation Pharmaceuticals Inc.

Total raised
$286 M
7 rounds on record
Latest round
$65 M
Oct 2019
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Constellation Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2019$65 MNo. 7$50 to $250 million

Constellation Pharmaceuticals Inc.: Raise no. 7, Oct 2019

Investors in this round

11 investors had bought by the notice of Oct 8, 2019: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adrian G. Senderowicz · Executive Officer
  • Emma E. Reeve · Executive Officer
  • Jigar Raythatha · Executive Officer, Director
  • Karen G. Valentine · Executive Officer
  • Patrick G. Trojer · Executive Officer
  • Anthony Evnin · Director
  • Elizabeth G. Trehu · Director
  • James E. Audia · Director
  • Mark A. Goldsmith · Director
  • Robert A. Tepper · Director
  • Scott G. Braunstein · Director
  • Steven G. Hoerter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emma Reeve, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 8, 2019. Read the notice at the SEC.

equitySEC
Mar 2018$99 MNo. 6$50 to $250 million

Constellation Pharmaceuticals Inc.: Raise no. 6, Mar 2018

Investors in this round

30 investors had bought by the notice of Apr 6, 2018: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$99 M of $100 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Emma E. Reeve · Executive Officer
  • Jigar Raythatha · Executive Officer, Director
  • Anthony Evnin · Director
  • James E. Audia · Director
  • Mark A. Goldsmith · Director
  • Peter Svennilson · Director
  • Robert A. Tepper · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emma Reeve, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 6, 2018. Read the notice at the SEC.

equitySEC
Sep 2016$24 MNo. 5$10 to $50 million

Constellation Pharmaceuticals Inc.: Raise no. 5, Sep 2016

Investors in this round

17 investors had bought by the notice of Sep 27, 2016: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$24 M of $24 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James E. Audia · Executive Officer
  • Mark A. Goldsmith · Executive Officer, Director
  • Matthias E. Jaffe · Executive Officer
  • Michael R. Cooper · Executive Officer
  • Anthony A. Evnin · Director
  • Peter A. Svennilson · Director
  • Robert A. Tepper · Director
  • Tom A. Maniatis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Goldsmith, Chairman. Source: SEC Form D, newest notice filed Sep 27, 2016. Read the notice at the SEC.

equitySEC
Dec 2015$56 MNo. 4$50 to $250 million

Constellation Pharmaceuticals Inc.: Raise no. 4, Dec 2015

Investors in this round

22 investors had bought by the notice of Dec 15, 2015: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $56 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James E. Audia · Executive Officer
  • Keith Dionne · Executive Officer, Director
  • Matthias E. Jaffe · Executive Officer
  • Michael R. Cooper · Executive Officer
  • Anthony Evnin · Director
  • David A. Goeddel · Director
  • Mark A. Goldsmith · Director
  • Robert A. Tepper · Director
  • Tom A. Maniatis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Keith Dionne, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 15, 2015. Read the notice at the SEC.

equitySEC
Aug 2014$5 MNo. 3$2 to $10 million

Constellation Pharmaceuticals Inc.: Raise no. 3, Aug 2014

Investors in this round

8 investors had bought by the notice of Aug 5, 2014: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James E. Audia · Executive Officer
  • Keith Dionne · Executive Officer, Director
  • Matthias E. Jaffe · Executive Officer
  • Michael R. Cooper · Executive Officer
  • Anthony Evnin · Director
  • David A. Goeddel · Director
  • Mark A. Goldsmith · Director
  • Robert A. Tepper · Director
  • Steven A. Paul · Director
  • Tom A. Maniatis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Keith Dionne, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 5, 2014. Read the notice at the SEC.

equitySEC
May 2011$15 MNo. 2$10 to $50 million

Constellation Pharmaceuticals Inc.: Raise no. 2, May 2011

Investors in this round

7 investors had bought by the notice of Jun 6, 2011: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Garen E. Bohlin · Executive Officer
  • James E. Audia · Executive Officer
  • Mark A. Goldsmith · Executive Officer, Director
  • Michael R. Cooper · Executive Officer
  • Anthony Evnin · Director
  • David Goeddel · Director
  • Mark A. Levin · Director
  • Robert E. Tepper · Director
  • Steven E. Paul · Director
  • Tom A. Maniatis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark A. Goldsmith, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 6, 2011. Read the notice at the SEC.

equity, optionsSEC
May 2010$22 MNo. 1$10 to $50 million

Constellation Pharmaceuticals Inc.: Raise no. 1, May 2010

Investors in this round

9 investors had bought by the notice of Jun 2, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 33 investors are named for Constellation Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$22 M of $22 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edward E. Harlow, Jr. · Executive Officer
  • Garen E. Bohlin · Executive Officer
  • Kerry K. Reinertsen · Executive Officer
  • Mark A. Goldsmith · Executive Officer, Director
  • Anthony Evnin · Director
  • David Goeddel · Director
  • Mark A. Levin · Director
  • Robert K. Tepper · Director
  • Tom A. Maniatis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark A. Goldsmith, President, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 2, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Constellation Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).

    SEC Form D · Oct 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2019

That is all the official record says: Constellation Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

33 named in official filings. Open an investor to see everything it has backed.

Investors in Constellation Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Casdin Capital, LLCFund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Casdin Partners GP, LLCFund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Casdin Partners Master Fund, L.P.Fund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Casdin Venture Opportunities Fund GP, LLCVenture capitalnot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Casdin Venture Opportunities Fund, L.P.Venture capitalnot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Column Group GP, LPFund or asset managernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Column Group L.P.Fund or asset managernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Cormorant Private Healthcare Fund I, LPFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
LG Management, LLCFund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Mountain Berg LtdCompanynot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
OrbiMed Global Healthcare GP LLCOthernot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Ponoi Capital II, LPFund or asset managernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Ponoi Capital, LPFund or asset managernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Ponoi II Management, LLCFund or asset managernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Ponoi Management, LLCFund or asset managernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Precision Onco LtdCompanynot statednot statedHeld Series F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Regents Of The University Of CaliforniaFund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Spur Capital Partners LLCFund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Spur Ventures II, LPVenture capitalnot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Third Rock Ventures GP, L.P.Venture capitalnot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Third Rock Ventures LPVenture capitalnot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Topspin Biotech Fund II, L.P.Fund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Topspin Fund L.P.Fund or asset managernot statednot statedHeld Series E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3
TRV GP, LLCOthernot statednot statedHeld Series A, B, D, E, E-1 and F preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 7 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Constellation Pharmaceuticals Inc.
NameRoleNamed in
Adrian G. SenderowiczExecutive officerOct 2019
Emma E. ReeveExecutive officerOct 2019
Jigar RaythathaExecutive officerOct 2019
Karen G. ValentineExecutive officerOct 2019
Patrick G. TrojerExecutive officerOct 2019
James E. AudiaExecutive officerSep 2016
Mark A. GoldsmithExecutive officerSep 2016
Matthias E. JaffeExecutive officerSep 2016
Michael R. CooperExecutive officerSep 2016
Keith DionneExecutive officerDec 2015
Garen E. BohlinExecutive officerJun 2011
Edward E. Harlow, Jr.Executive officerJun 2010
Kerry K. ReinertsenExecutive officerJun 2010
Anthony EvninDirectorOct 2019
Elizabeth G. TrehuDirectorOct 2019
James E. AudiaDirectorOct 2019
Jigar RaythathaDirectorOct 2019
Mark A. GoldsmithDirectorOct 2019
Robert A. TepperDirectorOct 2019
Scott G. BraunsteinDirectorOct 2019
Steven G. HoerterDirectorOct 2019
Peter SvennilsonDirectorApr 2018
Anthony A. EvninDirectorSep 2016
Peter A. SvennilsonDirectorSep 2016
Tom A. ManiatisDirectorSep 2016
David A. GoeddelDirectorDec 2015
Keith DionneDirectorDec 2015
Steven A. PaulDirectorAug 2014
David GoeddelDirectorJun 2011
Mark A. LevinDirectorJun 2011
Robert E. TepperDirectorJun 2011
Steven E. PaulDirectorJun 2011
Robert K. TepperDirectorJun 2010

About

Company in Cambridge, United States.